Previous 10 |
home / stock / argnf / argnf news
argenx SE (ARGX) Q4 2020 Results Conference Call March 04, 2021 08:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Eric Castaldi - Chief Financial Officer Keith Woods - Chief Operatin...
The following slide deck was published by argenx SE in conjunction with this event. For further details see: argenx (ARGX) Investor Presentation - Slideshow
argenx SE (ARGX) Q3 2020 Earnings Conference Call October 22, 2020 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Eric Castaldi - Chief Financial Officer Conference Call P...
The following slide deck was published by argenx SE in conjunction with their 2020 Q3 earnings call. For further details see: argenx SE 2020 Q3 - Results - Earnings Call Presentation
ARGX is up nearly 15-fold since we first covered it positively in 2017. Now that it is approaching the market for the current lead indication, we still see some upside to the stock. We think it is a long term hold-able stock. For further details see: Argenx: Competitive ...
argenx SE (ARGX) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Eric Castaldi - Chief Financial Officer ...
The following slide deck was published by argenx SE in conjunction with their 2020 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Ju...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— ...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...